Description: LOX-1, Human, mAb 23C11

The monoclonal antibody 23C11 recognizes oxidized low-density lipoprotein receptor-1 (LOX-1). LOX-1 is a single-pass type II membrane protein (~45 kDa) and belongs to the C-type lectin-like protein superfamily. LOX-1 is expressed at high level in endothelial cells and vascular-rich organs such as placenta, lung, liver, brain aortic intima, bone marrow, spinal cord and substantia nigra. It is also expressed on the surface of dendritic cells. This unique scavenger receptor LOX-1 plays important roles in atherogenesis. LOX-1 mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis, inducing vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. LOX-1 associates with oxLDL inducing the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, LOX-1 acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. LOX-1 is involved in the inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. LOX-1 also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria. The LOX-1 gene is a so-called immediate early gene that is dynamically modulated by several factors in vitro and in vivo. LOX-1 expression is induced by stimuli such as inflammatory cytokines, OxLDL, TNF-alpha, TGF-beta, and ANG II in vitro, and several proatherogenic factors in vivo. Monoclonal antibody 23C11 neutralizes LOX-1 and inhibits Hsp70 binding to dendritic cells and Hsp70-induced antigen cross-presentation. In vivo, targeting LOX-1 with a tumor antigen using anti-LOX-1 antibody 23C11 induces anti-tumor immunity.

Specifications:

Catalog number Product type Quantity Formulation Application Application Notes Use Immunogen Isotype Species Cross reactivity Alias Positive Control References Storage and stability Precautions Disease

HM2138

Monoclonal antibodies

100 µg

1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.

Flow cytometry, Functional studies, Immuno fluorescence

FC: 10µg/ml antibody used on human peripheral blood myeloid DC and macrophages FS: antibody totally prevented Hsp70 binding to LOX-1-CHO but not mock-transfected CHO cells (Ref 1)

For flow cytometry dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in users experimental settting.

Fusion protein of extracellular domain (aa 71-273) of human LOX-1 with murine Fcγ1 (LOX-1-muFc) produced in PEAK cells

Mouse IgG1

Human

Mouse - Yes

Lectin-like oxidized LDL receptor 1, Ox-LDL receptor 1, C-type lectin domain family 8 member A

Human APCs

1. Delneste, Y et al; Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002, 17: 3532. Jeannin, P et al; Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 2005, 22: 5513. Parlato, S et al; LOX-1 as a natural IFN-;-mediated signal for apoptotic cell uptake and antigen presentation in edndritic cells. Blood 2010, 115: 1554

Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year.

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result with the use or derivation of this product.

Cardiology and metabolism